The - Chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Ĭhapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The - Chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Ĭhapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Ĭhapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities.Ĭhapter 1 provides an introduction to the reportĬhapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.Ĭhapter 3 provides a review of the leading antibiotics deals since 2010. The report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering: These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The leading antibiotics partnering resources Most active antibiotics dealmakers since 2010 The leading antibody deals by value since 2010 Trends in antibiotics dealmaking in the biopharma industry since 2010Īccess to headline, upfront, milestone and royalty dataĬase studies of real-life antibiotics dealsĪccess to over 300 antibiotics deal records and contract documents where available
This report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Dublin, (GLOBE NEWSWIRE) - The "Global Antibiotics Partnering Terms and Agreements 2010 to 2020" report has been added to 's offering.
0 kommentar(er)
